LIGHT deficiency aggravates cisplatin-induced acute kidney injury by upregulating mitochondrial apoptosis

被引:11
|
作者
Yang, Yan [1 ,2 ,3 ]
Menga, Li [1 ]
Wu, Shun [4 ]
Li, You [3 ]
Zhong, Yu [1 ]
Xu, Feng [2 ]
Zhou, Xiao-cui [5 ]
Li, Gui-qing [2 ]
Xu, Gui-lian [2 ]
Peng, Kan-fu [1 ]
机构
[1] Third Mil Med Univ, Army Med Univ, Affiliated Hosp 1, Dept Nephrol, Chongqing 400038, Peoples R China
[2] Third Mil Med Univ, Army Med Univ, Dept Immunol, Chongqing 400038, Peoples R China
[3] Third Mil Med Univ, Army Med Univ, Daping Hosp, Dept Intens Care Med,Affiliated Hosp 3, Chongqing 400042, Peoples R China
[4] Xuzhou Med Univ, Huaihai Hosp, Dept Nephrol, Xuzhou 221004, Jiangsu, Peoples R China
[5] Chongqing Med & Pharmaceut Coll, Affiliated Hosp 1, Dept Intens Care Med, Chongqing 400006, Peoples R China
基金
中国国家自然科学基金;
关键词
LIGHT; Cisplatin; Acute kidney injury; Mitochondrial apoptosis; HERPESVIRUS ENTRY MEDIATOR; SUPERFAMILY; RECEPTOR; ACTIVATION; PATHWAYS; MEMBER; FAMILY; CELLS; BTLA;
D O I
10.1016/j.intimp.2020.106999
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cisplatin is widely used as a chemotherapeutic agent for treating patients with solid tumors. The most common side effect of cisplatin treatment is nephrotoxicity. Recent studies have shown that mitochondrial apoptotic pathways are involved in cisplatin-induced acute kidney injury (Cis-AKI). LIGHT, the 14th member of the tumor necrosis factor superfamily (TNFSF14), was found to induce apoptosis of certain types of tumor cells. So far, a link between LIGHT and Cis-AKI has not been reported. In this study, we observed that expression of LIGHT and its receptors HVEM and LT beta R was increased in kidney tissues of mice after cisplatin treatment. LIGHT deficiency aggravated kidney injury, as evidenced by more severe tubular injury; remarkably increased levels of serum creatinine (Scr), blood urea nitrogen (BUN), and both kidney injury molecule-1 (KIM-1) and inflammatory cytokine mRNAs in renal tissues. Moreover, in the renal tissues of LIGHT KO mice, cisplatin-induced mitochondrion injury and the levels of the pro-apoptotic molecules Bax, Cytochrome C (Cyt C), cleaved caspase-3, and cleaved caspase-9 were dramatically increased; in contrast, the expression of anti-apoptotic molecule Bcl-2 was markedly reduced, compared to those in WT mice, suggesting that LIGHT deficiency accelerated cisplatin-induced mitochondrial apoptosis of renal tubular cells in these mice. Accordingly, treatment with recombinant human LIGHT (rLIGHT) was shown to alleviate cisplatin-induced kidney injury in vivo. Similar results were observed after the human renal tubular epithelial cell line HK-2 cells exposure to rLIGHT stimulation, evidenced by the reduction in the mitochondrion dysfunction (as confirmed by the significant reduced oxidative stress and membrane potential changes) and in the percentage of cells apoptosis. While blocking LIGHT with the soluble fusion protein LT beta R-Ig or HVEM-Ig accelerated the HK-2 cells apoptosis. In conclusion, LIGHT deficiency aggravates Cis-AKI by promoting mitochondrial apoptosis pathways.y
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Inhibition of PTEN activity aggravates cisplatin-induced acute kidney injury
    Zhou, Jun
    Fan, Youling
    Tang, Simin
    Wu, Huiping
    Zhong, Jiying
    Huang, Zhengxing
    Yang, Chengxiang
    Chen, Hongtao
    ONCOTARGET, 2017, 8 (61) : 103154 - 103166
  • [2] Intervention of mitochondrial activity attenuates cisplatin-induced acute kidney injury
    Yunwen Yang
    Yu Fu
    Peipei Wang
    Suwen Liu
    Yugen Sha
    Yue Zhang
    Aihua Zhang
    Zhanjun Jia
    Guixia Ding
    Songming Huang
    International Urology and Nephrology, 2019, 51 : 1207 - 1218
  • [3] Intervention of mitochondrial activity attenuates cisplatin-induced acute kidney injury
    Yang, Yunwen
    Fu, Yu
    Wang, Peipei
    Liu, Suwen
    Sha, Yugen
    Zhang, Yue
    Zhang, Aihua
    Jia, Zhanjun
    Ding, Guixia
    Huang, Songming
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (07) : 1207 - 1218
  • [4] Pathophysiology of Cisplatin-Induced Acute Kidney Injury
    Ozkok, Abdullah
    Edelstein, Charles L.
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [5] Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury
    Sears, Sophia M.
    Dupre, Tess, V
    Shah, Parag P.
    Davis, Deanna L.
    Doll, Mark A.
    Sharp, Cierra N.
    Vega, Alexis A.
    Megyesi, Judit
    Beverly, Levi J.
    Snider, Ashley J.
    Obeid, Lina M.
    Hannun, Yusuf A.
    Siskind, Leah J.
    JOURNAL OF LIPID RESEARCH, 2022, 63 (03)
  • [6] TAK1 deficiency attenuates cisplatin-induced acute kidney injury
    Zhou, Jun
    An, Changlong
    Jin, Xiaogao
    Hu, Zhaoyong
    Safirstein, Robert L.
    Wang, Yanlin
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2020, 318 (01) : F209 - F215
  • [7] Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury
    Mapuskar, Kranti A.
    Steinbach, Emily J.
    Zaher, Amira
    Riley, Dennis P.
    Beardsley, Robert A.
    Keene, Jeffery L.
    Holmlund, Jon T.
    Anderson, Carryn M.
    Zepeda-Orozco, Diana
    Buatti, John M.
    Spitz, Douglas R.
    Allen, Bryan G.
    ANTIOXIDANTS, 2021, 10 (09)
  • [8] Carnosol alleviates cisplatin-induced acute kidney injury by regulating apoptosis and pyroptosis
    Li, Chunjie
    Yang, Hongyan
    Wu, Yuan
    Zhou, Mingke
    Luo, Hengbiao
    Yuan, Peng
    Shen, Fengge
    CELL BIOLOGY INTERNATIONAL, 2025, 49 (01) : 101 - 117
  • [9] RTN3 deficiency exacerbates cisplatin-induced acute kidney injury through the disruption of mitochondrial stability
    Du, Ran
    Liu, Ji-Shi
    Huang, Hao
    Liu, Yu -Xing
    Jin, Jie-Yuan
    Wang, Chen -Yu
    Dong, Yi
    Fan, Liang-Liang
    Xiang, Rong
    MITOCHONDRION, 2024, 75
  • [10] The potency of obestatin in improving kidney functions and apoptosis in rats with cisplatin-induced acute kidney injury
    Ozdemir Kumral, Zarife Nigar
    Bulut, Alisina
    Uzulmez, Bahadir
    Vezirhuyuk, Mustafa
    Kok, Zafer
    Ozkan Yenal, Naziye
    Yegen, Berrak C.
    Koc, Mehmet
    JOURNAL OF RESEARCH IN PHARMACY, 2022, 26 (05): : 1375 - 1385